Open AccessMay the development of type 2 diabetes mellitus be prevented: Results of the Stop-NDDM sudy
Author(s) -
I. Chazova
Publication year - 2003
Publication title -
arterialʹnaâ gipertenziâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 5
eISSN - 2411-8524
pISSN - 1607-419X
DOI - 10.18705/1607-419x-2003-9-3-88-91
Subject(s) - acarbose , medicine , type 2 diabetes mellitus , myocardial infarction , diabetes mellitus , placebo , stroke (engine) , type 2 diabetes , relative risk , insulin resistance , insulin , cardiology , endocrinology , confidence interval , pathology , mechanical engineering , alternative medicine , engineering
There are about 150 million patients with diabetes mellitus (DM) in the world and their number will double by 2025. The occurrence of a complete clinical picture of type DM follows a period of glucose intolerance (GI). Enhancing insulin sensitivity and thus affecting GI may prevent the development of type 2 DM and reduce a risk of cardiovascular events. Acarbose (glucobay) is one of the drugs that affect insulin resistance. In the Stop-NDDM study enrolled patients with NI and obesity treated with acarbose for 3 years, the relative risk of type 2 DM decreased by 25% as compared with that in the placebo group. Active therapy caused a reduction in the relative risk of myocardial infarction by 91%, myocardial revascularization procedures by 39%, cerebrovascular disorders and stroke by 44%, and cardiovascular death by 45%.